Test
213 articles
Blood-Based Test Predicts What Drugs May Work Best
Dr. Kenneth Yu is testing a blood-based assay that looks at which types of chemotherapies will work best for each pancreatic cancer patient.
Using AI to Create a Better Test to Predict Pancreatic Cancer Progression
Dr. Dan Theodorescu is using AI to isolate more effective biomarkers than the CA 19-9 test to track pancreatic cancer progression.
Studying a New Approach for the Liquid Biopsy
Drs. Allyson Ocean and Ying-Hsiu Su lead a liquid biopsy pilot study looking for KRAS proteins in urine, to detect pancreatic cancer.
A Liquid Biopsy for Pancreatic Cancer
Dr. Bert Vogelstein and his team at Johns Hopkins are working with a blood test called a liquid biopsy, which tests cells for mutations related to cancer.
GENERATE Study Aims to Improve Genetic Testing and Prevention for Pancreatic Cancer
Dr. Sapna Syngal outlines the GENERATE study, which aims to help families with a risk for pancreatic cancer by providing genetic testing.
Liquid Biopsies and the Status of Pancreatic Cancer Screening
Dr. Conan Kinsey discusses the usefulness of liquid biopsies for pancreatic cancer screening and early detection.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
Patients Needed for Clinical Trial/Research Study of Treatment Targeting Immune System
A clinical trial seeks pancreatic cancer patients with the MSI (microsatellite instability) genetic signature, to test an immunotherapy drug.
Machine-Learning Assay May Improve Pancreatic Cyst Management
Dr. Anne Marie Lennon explains CompCyst, the artificial intelligence-based assay that can determine the best treatment for pancreatic cysts.
Tumor Genetics Research Brings Some Answers for Families at High Risk
Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Personalizing Pancreatic Cancer Treatment
Dr. Mark Ricigliano takes a closer look at the genetics of circulating tumor cells, to personalize pancreatic cancer treatment for the best results.
PLATINUM Clinical Trial Actively Recruiting
The PLATINUM clinical trial, for patients with BRCA and PALB2 mutations, seeks participants. Dr. Andrew Ko outlines the trial.
Reducing Pancreatic Cancer Risk Through Chemoprevention
Dr. Peter Allen leads a clinical trial of chemoprevention–the use of a medication to prevent IPMNs from developing into pancreatic cancer.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.